Investment landscape in biotechnology and health technology has been changing. What lies ahead of the entrepreneur community and what opportunities and challenges the Year of Snake holds? Reed Smith LLP and InnoSpring are co-hosting a panel at InnoSpring on February 13, 2013. Among the issues discussed:
- Investment trends for biotechnology and health technology in the United States and China
- Outlook of the entrepreneur community in biotechnology and health technology
- Impacts of FDA/SFDA regulations
Hopefully, this program will elicit more discussions about the opportunities and challenges if you are a health technology entrepreneur, or an investor. Panelists with in-depth venture capital, industrial and legal backgrounds will share insights.
Time: 18:30-20:30, February 13 (Wednesday), 2013
Venue: InnoSpring, 2901 Tasman Drive, Suite 107, Santa Clara, CA 95054
18:30-19:00 Sign-in and Networking
19:00-20:00 Panel discussion
Catharina Y. Min Partner, Reed Smith LLP
David J. Woodhouse Managing Director, Goldman Sachs
Jack Young Director, Qualcomm Life Fund, Qualcomm Ventures
Alex De Winter Director, Healthymagination Fund, GE Ventures
Jackie Yang Co-founder and Managing Director, TransLink Capital
Gordon B. Schatz Partner, Reed Smith LLP
We enthusiastically welcome you to this event! Join us and register here.
David is a member of Healthcare Investment Banking and is responsible for Biotech and Life Science company coverage in the West Region of the United States. Previously, he was a vice president in Healthcare Investment Banking for four years. David joined Goldman Sachs in 2002 as an associate in Healthcare Investment Banking in New York. He was named managing director in 2010.
Prior to joining the firm, David worked in business development and drug development research at Dynavax Technologies, Amgen and Syntex.
David earned an MBA from the Tuck School of Business at Dartmouth College in 2002 and a PhD in Molecular Pharmacology in 1999 from the Stanford School of Medicine, where he was awarded a PhRMA Foundation fellowship in support of his thesis work. He earned a BA in Pharmacology, with honors, from the University of California, Santa Barbara, in 1992.
Jack heads up the $100M Qualcomm Life Fund (QLF) at Qualcomm Ventures, which was recently ranked as one of the most prolific venture investors in the digital health sector. His investment interests are focused in the areas of digital technologies and wireless health services and applications including: wellness and fitness, chronic disease management, aging in place, transitional care, clinical trials and telehealth/telemedicine. Jack currently serves as a board observer at QLF portfolio companies including Airstrip, AliveCor, ClearCare, goBalto and Telcare. In addition, he serves as a board observer at Jana, Modern Video, uCIRRUS, Validity and Visage Mobile.
Prior to Qualcomm Ventures, Jack was EVP and US Country Manager at ZTE who helped establish the company’s US market presence. He was a sales and marketing executive at Nokia following the acquisition of Amber Networks where he was founding AVP of marketing. Early in his career, he held marketing and business development positions at 3Com, GDC, and Nortel. Jack earned a MSEE from University of Calgary and a MBA from McGill University.
Alex is a director at GE Ventures, with the Healthymagination Fund, where he invests in life science tools, clinical diagnostics, and big data related to healthcare. Prior to GE, Alex was a partner at Mohr Davidow Ventures. At Mohr Davidow, Alex was a board director at On-Q-ity, as well as a board observer for CardioDx, Corventis, Crescendo Bioscience, didimi, DVS Sciences, and Personalis. He started his career as a research scientist with 454 Life Sciences and Pacific Biosciences.
Alex has an MBA from UC Berkeley, a Ph.D. from Stanford, and graduated magna cum laude from Amherst College.
Mr. Jackie Yang is a co-founder and Managing Director of TransLink Capital. He brought over 15 years of venture investment experience to the team and was one of the most active investors in the semiconductor industry during that period. Jackie is responsible for TransLink’s investments in Montage, WinKing, Sandforce (Acquried by LSI), TangoMe, Adwo and Memoright.
Before starting TransLink, Jackie was the Senior Vice President at UMC Capital and was responsible for UMC’s investment activities in the United States and China. During his tenure at UMC Capital, he was the founding investor in Maxlinear, Inc. (NYSE:MXL), Montage Technology Group and Parade Technologies, Ltd.(4966.TWO), and served on the board of Praesagus (acquired by Cadence Design System), WisChip (acquired by Micronas), Triscend (acquired by Xilinx), ForteMedia, Aicent, Inc., and Aurora Systems (acquired by OmniVision). He was also responsible for other portfolio companies included Silicon Wave Inc. (acquired by RF Micro Devices), Spreadtrum Communications Inc. (NASDAQ: SPRD), and Intellon Corporation (NASDAQ: ITLN, acquired by Atheros – NASDAQ:ATHR).
Jackie received his MBA degree from University of Missouri – Columbia and BS degree in Mechanical Engineering from National Tsinghua University – Taiwan.
Gordon is a member of the Life Sciences Health Industry Group, practicing in the area of health care regulatory law and serving as integration partner for the firm’s China offices. He works closely with the Shanghai and Beijing offices to assist the firm’s clients in rapidly accessing our China lawyers. In coordination with our colleagues in Shanghai and Beijing, Gordon helps pharmaceutical, medical device, health care, and other clients start operations in China, clear regulatory hurdles, develop business ties with Chinese companies, and set up distribution and sales networks.
Gordon chaired the Food and Drug Law Institute Panel on Innovation at its 2011 Beijing conference, and has lectured on Innovation, Regulation, and the Health Care Industry, at the Tsinghua Law School Health Law Research Center (Beijing). In the United States, Gordon represents device, drug and diagnostic manufacturers on technology reimbursement, obtaining coverage, codes, and payment to advance innovative products before the Centers for Medicare & Medicaid Services (“CMS”), state agencies, and the U.S. Congress. Also, he advises manufacturers and health care providers on compliance with federal and state fraud and abuse laws, including sales, promotional, and marketing programs. Within Reed Smith, Gordon served as co-chair of the firm’s Life Sciences Team and Health Care Group Practice Leader.
Catharina is the Office Managing Partner at the Silicon Valley office. She practices corporate and M & A law with an emphasis in representing both U.S. and international clients in mergers and acquisitions, private financings, joint ventures, strategic alliances, corporate partnering, securities offerings and other corporate transactions. She also represents emerging companies in general corporate matters and venture capital financings. In addition, she has extensive experience representing Asian clients doing business in the United States.
She is a frequent speaker at many organizations, including the SV Forum and the Korean IT Network, covering topics related to cross-border transactions and venture capital financings.
About Reed Smith LLP
Reed Smith is a global relationship law firm with more than 1,700 lawyers in 25 offices throughout the United States, Europe, Asia and the Middle East. Founded in 1877, the firm represents leading international businesses, from Fortune 100 corporations to mid-market and emerging enterprises. Its lawyers provide litigation and other dispute resolution services in multi-jurisdictional and high-stake matters, deliver regulatory counsel, and execute the full range of strategic domestic and cross-border transactions. Reed Smith is a preeminent advisor to industries including financial services, life sciences, health care, advertising, technology and media, shipping, energy trade and commodities, real estate, manufacturing, and education. For more information, visit http://www.reedsmith.com/
Special thanks to our partner CABS
The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry, headquartered in San Francisco, California. Three quarters of the members have a doctorate degree and approximately half of them hold leadership and management positions in the biopharmaceutical industry. One of CABS’ new initiatives is the CABS entrepreneur club (E-club), which aims to foster the spirit of entrepreneurship and to provide a forum for networking among current and aspiring CABS entrepreneurs. Visit CABS at http://www.cabsweb.org/CABSweb/home_page.jsp